Result of AGM
Cambridge Cognition Holdings plc announced that all resolutions were passed at its Annual General Meeting, with proxy votes received for 59.3% of the issued share capital. Key resolutions, including the approval of the 2025 Report and Accounts and the appointment of auditors, received overwhelming support, with 100% and 99.92% of votes cast in favour respectively. The re-election of directors and the election of new directors also passed with high percentages, generally above 99.9%. Resolutions concerning the authority to allot shares and disapply pre-emption rights were approved by 99.79% and 99.80% of votes cast, respectively, while the authority to purchase own shares received 99.90% approval.
Select text to share a quote on X · sign in to keep highlights & notes in your COG notes
Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, held its Annual General Meeting ("AGM") earlier today at the registered office of the Company; Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU and announces that all resolutions put forward were duly passed.
Proxy votes were received in respect of 59.3% of the Company's issued share capital. The votes cast were as follows:
| Resolution | Votes For | Percent of votes cast For | Votes Against | Percent of votes cast Against | Votes Withheld | |
|---|---|---|---|---|---|---|
| 1 | To approve the 2025 Report and Accounts | 27,607,286 | 100% | - | - | 22,265 |
| 2 | To approve the 2025 Directors' Remuneration Report 1 | 27,576,829 | 99.83% | 47,714 | 0.17% | 5,008 |
| 3 | To appoint the auditors | 27,595,679 | 99.92% | 22,660 | 0.08% | 11,212 |
| 4 | To authorise the Directors to set the auditors' remuneration | 27,602,281 | 99.99% | 2 | 0.01% | 27,268 |
| 5 | To re-elect Stuart Gall as a Director | 27,602,093 | 99.92% | 22,440 | 0.08% | 5,018 |
| 6 | To re-elect Jon Kempster as a Director | 27,601,693 | 99.92% | 22,840 | 0.08% | 5,018 |
| 7 | To re-elect Nick Rodgers as a Director | 27,601,693 | 99.92% | 22,840 | 0.08% | 5,018 |
| 8 | To elect Rob Baker as a Director | 27,602,273 | 99.92% | 22,260 | 0.08% | 5,018 |
| 9 | To elect Ronald Openshaw as a Director | 27,602,273 | 99.92% | 22,260 | 0.08% | 5,018 |
| 10 | Authority to allot shares | 27,572,233 | 99.79% | 57,313 | 0.21% | 5 |
| 11 | Authority to disapply pre-emption rights 2 | 27,569,635 | 99.80% | 54,898 | 0.20% | 5,018 |
| 12 | Authority to purchase own shares on the market 2 | 24,196,722 | 99.90% | 25,412 | 0.10% | 3,407,417 |
Notes
- Indicates an advisory vote.
- Indicates a Special Resolution requiring 75% of votes cast to be carried.
- Clinical Studies for new pharmaceuticals;
- Academic Research for scientists to understand CNS disorders;
- Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,
- Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.
For further information, visit: www.cambridgecognition.com.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.